-
2024-520043-17-00
Thromboprophylaxis in patients with advanced pancreatic 5
-
2025-521775-31-00
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
-
2024-514459-14-00
Non-Small Cell Lung Cancer 4 2025-04-22
-
2022-502825-17-00
Melanoma 4 2024-10-07
-
2022-501105-12-00
Urothelial Carcinoma 5 2024-07-15
-
2022-501007-28-00
Breast Neoplasms 5 2023-04-18
-
2022-502352-31-00
Colorectal Cancer (CRC) 5 2025-02-10
-
2024-513087-26-00
Metastatic Non-small Cell Lung Cancer 5 2024-09-10
-
2023-506308-24-00
Recurrent or metastatic head and neck squamous cell car 10 2024-05-22
-
2022-502357-34-00
Extensive Stage Small Cell Lung Cancer 5 2023-09-27
-
2024-513621-23-00
Advanced/metastatic non-small cell lung cancer (NSCLC) 5 2025-04-18
-
2022-501483-18-00
Advanced Non-Small Cell Lung Cancer 10 2025-03-28
-
2024-512998-27-00
Non-Small Cell Lung Cancer 5 2025-02-21
-
2023-504753-12-00
Lung Cancer, Non-Small Cell 5 2024-10-01
-
2023-504515-33-00
Melanoma 4 2024-02-19
-
2023-503827-25-01
Non-Small Cell Lung Cancer (NSCLC) 5 2024-02-16
-
2023-503575-21-00
Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23
-
2022-500802-16-00
Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non- 5 2023-11-01
-
2022-501576-25-00
Melanoma 5 2023-07-07
-
2022-502145-10-00
Hormone Receptor (HR)-Positive, Human Epidermal Growth 5 2023-06-06
-
2024-511169-12-00
Non-Small Cell Lung Cancer 5 2023-03-28
-
2023-507933-12-00
Advanced or Metastatic Non-small Cell Lung Cancer (NSCL 5 2022-08-18
-
2023-503333-22-00
Moderate to severe controlled asthma according to Step 5 2024-01-15
-
2023-504270-38-00
In participants with PD-L1–positive and systemic therap 4 2022-10-18